328 related articles for article (PubMed ID: 27587537)
1. The Selective Nav1.7 Inhibitor, PF-05089771, Interacts Equivalently with Fast and Slow Inactivated Nav1.7 Channels.
Theile JW; Fuller MD; Chapman ML
Mol Pharmacol; 2016 Nov; 90(5):540-548. PubMed ID: 27587537
[TBL] [Abstract][Full Text] [Related]
2. Lidocaine Binding Enhances Inhibition of Nav1.7 Channels by the Sulfonamide PF-05089771.
Jo S; Bean BP
Mol Pharmacol; 2020 Jun; 97(6):377-383. PubMed ID: 32193331
[TBL] [Abstract][Full Text] [Related]
3. Lacosamide Inhibition of Nav1.7 Voltage-Gated Sodium Channels: Slow Binding to Fast-Inactivated States.
Jo S; Bean BP
Mol Pharmacol; 2017 Apr; 91(4):277-286. PubMed ID: 28119481
[TBL] [Abstract][Full Text] [Related]
4. Addition of a single methyl group to a small molecule sodium channel inhibitor introduces a new mode of gating modulation.
Wang L; Zellmer SG; Printzenhoff DM; Castle NA
Br J Pharmacol; 2015 Oct; 172(20):4905-18. PubMed ID: 26220736
[TBL] [Abstract][Full Text] [Related]
5. Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels.
McCormack K; Santos S; Chapman ML; Krafte DS; Marron BE; West CW; Krambis MJ; Antonio BM; Zellmer SG; Printzenhoff D; Padilla KM; Lin Z; Wagoner PK; Swain NA; Stupple PA; de Groot M; Butt RP; Castle NA
Proc Natl Acad Sci U S A; 2013 Jul; 110(29):E2724-32. PubMed ID: 23818614
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology of the Na
Osteen JD; Sampson K; Iyer V; Julius D; Bosmans F
Proc Natl Acad Sci U S A; 2017 Jun; 114(26):6836-6841. PubMed ID: 28607094
[TBL] [Abstract][Full Text] [Related]
7. Enhancing inactivation rather than reducing activation of Nav1.7 channels by a clinically effective analgesic CNV1014802.
Zheng YM; Wang WF; Li YF; Yu Y; Gao ZB
Acta Pharmacol Sin; 2018 Apr; 39(4):587-596. PubMed ID: 29094728
[TBL] [Abstract][Full Text] [Related]
8. New aryl and acylsulfonamides as state-dependent inhibitors of Na
Zidar N; Tomašič T; Kikelj D; Durcik M; Tytgat J; Peigneur S; Rogers M; Haworth A; Kirby RW
Eur J Med Chem; 2023 Oct; 258():115530. PubMed ID: 37329714
[TBL] [Abstract][Full Text] [Related]
9. Mexiletine Block of Voltage-Gated Sodium Channels: Isoform- and State-Dependent Drug-Pore Interactions.
Nakagawa H; Munakata T; Sunami A
Mol Pharmacol; 2019 Mar; 95(3):236-244. PubMed ID: 30593458
[TBL] [Abstract][Full Text] [Related]
10. Identification of WB4101, an
Li M; Wu Y; Zou B; Wang X; Li M; Yu H
Mol Pharmacol; 2018 Aug; 94(2):896-906. PubMed ID: 29884692
[TBL] [Abstract][Full Text] [Related]
11. Veratridine modifies the gating of human voltage-gated sodium channel Nav1.7.
Zhang XY; Bi RY; Zhang P; Gan YH
Acta Pharmacol Sin; 2018 Nov; 39(11):1716-1724. PubMed ID: 29950616
[TBL] [Abstract][Full Text] [Related]
12. PF-06526290 can both enhance and inhibit conduction through voltage-gated sodium channels.
Wang L; Zellmer SG; Printzenhoff DM; Castle NA
Br J Pharmacol; 2018 Jul; 175(14):2926-2939. PubMed ID: 29791744
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive engineering of the tarantula venom peptide huwentoxin-IV to inhibit the human voltage-gated sodium channel hNa
Neff RA; Flinspach M; Gibbs A; Shih AY; Minassian NA; Liu Y; Fellows R; Libiger O; Young S; Pennington MW; Hunter MJ; Wickenden AD
J Biol Chem; 2020 Jan; 295(5):1315-1327. PubMed ID: 31871053
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Vixotrigine, a Broad-Spectrum Voltage-Gated Sodium Channel Blocker.
Hinckley CA; Kuryshev Y; Sers A; Barre A; Buisson B; Naik H; Hajos M
Mol Pharmacol; 2021 Jan; 99(1):49-59. PubMed ID: 33298520
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of Na
Swain NA; Batchelor D; Beaudoin S; Bechle BM; Bradley PA; Brown AD; Brown B; Butcher KJ; Butt RP; Chapman ML; Denton S; Ellis D; Galan SRG; Gaulier SM; Greener BS; de Groot MJ; Glossop MS; Gurrell IK; Hannam J; Johnson MS; Lin Z; Markworth CJ; Marron BE; Millan DS; Nakagawa S; Pike A; Printzenhoff D; Rawson DJ; Ransley SJ; Reister SM; Sasaki K; Storer RI; Stupple PA; West CW
J Med Chem; 2017 Aug; 60(16):7029-7042. PubMed ID: 28682065
[TBL] [Abstract][Full Text] [Related]
16. A complicated complex: Ion channels, voltage sensing, cell membranes and peptide inhibitors.
Zhang AH; Sharma G; Undheim EAB; Jia X; Mobli M
Neurosci Lett; 2018 Jul; 679():35-47. PubMed ID: 29684532
[TBL] [Abstract][Full Text] [Related]
17. Identification and Characterization of ProTx-III [μ-TRTX-Tp1a], a New Voltage-Gated Sodium Channel Inhibitor from Venom of the Tarantula Thrixopelma pruriens.
Cardoso FC; Dekan Z; Rosengren KJ; Erickson A; Vetter I; Deuis JR; Herzig V; Alewood PF; King GF; Lewis RJ
Mol Pharmacol; 2015 Aug; 88(2):291-303. PubMed ID: 25979003
[TBL] [Abstract][Full Text] [Related]
18. Three Peptide Modulators of the Human Voltage-Gated Sodium Channel 1.7, an Important Analgesic Target, from the Venom of an Australian Tarantula.
Chow CY; Cristofori-Armstrong B; Undheim EA; King GF; Rash LD
Toxins (Basel); 2015 Jun; 7(7):2494-513. PubMed ID: 26134258
[TBL] [Abstract][Full Text] [Related]
19. A Nav1.7 channel mutation associated with hereditary erythromelalgia contributes to neuronal hyperexcitability and displays reduced lidocaine sensitivity.
Sheets PL; Jackson JO; Waxman SG; Dib-Hajj SD; Cummins TR
J Physiol; 2007 Jun; 581(Pt 3):1019-31. PubMed ID: 17430993
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic Characterization of LTGO-33, a Selective Small Molecule Inhibitor of the Voltage-Gated Sodium Channel Na
Gilchrist JM; Yang ND; Jiang V; Moyer BD
Mol Pharmacol; 2024 Feb; 105(3):233-249. PubMed ID: 38195157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
